Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Since being discovered in 2008, the STING (stimulator of interferon genes) pathway has gradually been recognized as a central and promising target for immunotherapy. The STING pathway can be stimulated by cyclic dinucleotides (CDNs), leading to the type I interferons (IFN) production for immunotherapy for cancer or other diseases. However, the negative charges, hydrophilicity, and instability of CDNs have hindered their further applications. In addition, chronic activation of the STING pathway has been found to be involved in autoimmune diseases as IFN overproduction. Thus, research and development of STING agonists and inhibitors has been a hot field for the treatment of several diseases. The past several years, especially 2018, has seen increasingly rapid advances in this field. Here, this review summarizes the synthesis and modification of CDNs, the identification of nonnucleotide agonists, the recent progress in delivery systems and the medical applications, such as personalized vaccine adjuvants, in detail. In addition, in this review, we summarize the STING inhibitors’ advances from two aspects, covalent, and noncovalent inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
CGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.
Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695 · cited 1×
“2′,3′‐cGAMP is the endogenous secondary messenger engendered by cGAS.(5,7,8) CDG, CDA, and 3′,3′‐cGAMP are synthesized by bacteria and play a critical role in bacterial processes such as virulence.”
BackgroundSTING is a direct innate immune sensor of cyclic di-GMP
Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M., Hayakawa, Y., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10429 · Cited by 1,570
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560 · cited 6×
“Furthermore, RpRp dithio 2′,3′‐CDA was tested and behaved well in more challenging models, such as 4T1 and CT26.(27,61) Based on the results above, RpRp dithio 2′,3′‐CDA is being tested in phase I clinical trials by Aduro Biotech and Novartis.”
BackgroundMethodInfluentialNeoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313 · cited 1×
“On the other hand, chronic activation of the STING pathway may lead to autoimmune diseases such as systemic lupus erythematosus (SLE), Aicardi‐Goutières syndrome (AGS) and STING‐associated vasculopathy with onset in infancy (SAVI).(13) These types of pathogenesis could be attributed to mutations of nuclease and the ST…”
BackgroundTargeting STING with covalent small-molecule inhibitors
Haag, S. M., Gulen, M. F., Reymond, L., Gibelin, A., Abrami, L., Decout, A., Heymann, M., van der Goot, F. G., Turcatti, G., Behrendt, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0287-8 · Cited by 1,178 · cited 4×
“Through a cell‐based chemical screen, Ablasser et al identified two nitrofuran derivatives (C‐178, C‐176) that decreased the IFN‐β level induced by mouse, but not human, STING activation (Table 2).(87) To determine the mechanism, alanine‐scanning and mass spectrometry were conducted and they explored that compounds co…”
BackgroundMethodInfluentialAicardi–Goutières syndrome and the type I interferonopathies
Crow, Y. J., & Manel, N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3850 · Cited by 925
Diner, E. J., Burdette, D. L., Wilson, S. C., Monroe, K. M., Kellenberger, C. A., Hyodo, M., Hayakawa, Y., Hammond, M. C., & Vance, R. E. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.009 · Cited by 767 · cited 1×
“2′,3′‐cGAMP is the endogenous secondary messenger engendered by cGAS.(5,7,8) CDG, CDA, and 3′,3′‐cGAMP are synthesized by bacteria and play a critical role in bacterial processes such as virulence.”
BackgroundSTING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
cGAS is essential for the antitumor effect of immune checkpoint blockade
Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563
Jeremiah, N., Neven, B., Gentili, M., Callebaut, I., Maschalidi, S., Stolzenberg, M.-C., Goudin, N., Frémond, M.-L., Nitschke, P., Molina, T. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci79100 · Cited by 562 · cited 1×
“Similarly, gene mutations can induce a gain of function of the STING protein, which also brings about constitutive pathway activation with no need for CDNs stimulation (SAVI).(17,18) Therefore, inhibitors targeting STING are an attractive way to cure autoinflammatory diseases.”
BackgroundGall, A., Treuting, P., Elkon, K. B., Loo, Y.-M., Gale, M., Barber, G. N., & Stetson, D. B. (2012) · Immunity · doi:10.1016/j.immuni.2011.11.018 · Cited by 510
Signalling strength determines proapoptotic functions of STING
Gulen, M. F., Koch, U., Haag, S. M., Schuler, F., Apetoh, L., Villunger, A., Radtke, F., & Ablasser, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00573-w · Cited by 505
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.047 · Cited by 451 · cited 3×
“Furthermore, RpRp dithio 2′,3′‐CDA was tested and behaved well in more challenging models, such as 4T1 and CT26.(27,61) Based on the results above, RpRp dithio 2′,3′‐CDA is being tested in phase I clinical trials by Aduro Biotech and Novartis.”
MethodRole of the cGAS–STING pathway in cancer development and oncotherapeutic approaches
Khoo, L. T., & Chen, L. (2018) · The EMBO Reports · doi:10.15252/embr.201846935 · Cited by 204
Conjugated linoleic acid is a preferential substrate for fatty acid nitration
Bonacci, G., Baker, P. R. S., Salvatore, S. R., Shores, D., Khoo, N. K. H., Koenitzer, J. R., Vitturi, D. A., Woodcock, S. R., Golin-Bisello, F., Cole, M. P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.401356 · Cited by 147 · cited 1×
“NO2‐FAs are endogenously generated through the addition of nitrogen dioxide (NO2) to unsaturated fatty acids during viral infection.(89) NO2‐FAs, such as NO2‐cLA, 9‐NO2‐OA, and 10‐NO2‐OA (Table 2), could covalently modify STING at Cys88 and Cys91 to inhibit palmitoylation (Figure 16), leading to inactivation of the pa…”
Background
Cited by
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Prolonged activation of innate immune pathways by a polyvalent STING agonist
Li, S., Luo, M., Wang, Z., Feng, Q., Wilhelm, J., Wang, X., Li, W., Wang, J., Cholka, A., Fu, Y.-X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00675-9 · Cited by 317
Self-citationTrial watch: STING agonists in cancer therapy
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289
“intense wave of investigation aimed at the identification and development of pharmacological STING agonists for use in cancer patients.(9,68,91,92) Historically, flavone acetic acid (FAA)”
BackgroundTrial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Ni, H., Zhang, H., Li, L., Huang, H., Guo, H., Zhang, L., Li, C., Xu, J.-X., Nie, C.-P., Li, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005151 · Cited by 85
Metadata
- Authors
- Wu, J., Zhao, L., Hu, H., Li, W., & Li, Y.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2019-12-02
- Volume
- 40
- Issue
- 3
- Pages
- 1117-1141
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2993218757
- Cited by
- 157
- References
- 20
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.